2014 - DPhG

226 Pages·2014·5.62 MB·English

Annual Meeting of the D Annual Meeting of the German
P
German Pharmaceutical Society – DPhG h Pharmaceutical Society – DPhG
G

A
Frankfurt/Main n
n Trends and Perspectives in
September 24 – 26, 2014 u
a
at Goethe University l M Pharmaceutical Sciences
e
e
www.2014.dphg.de tin Conference Book
g

2
0
1
4

–

C
o
n
f
e
r
e
n
c
e

B
o Frankfurt/Main, September 24 – 26, 2014
o
k at Goethe University
ISBN 978-3-9816225-1-5 www.2014.dphg.de
Annual Meeting of the German
Pharmaceutical Society DPhG

Trends and Perspectives in
Pharmaceutical Sciences
Conference Book

Frankfurt/Main, September 24 26, 2014
at Goethe University
www.2014.dphg.de
Sponsors of the DPhG Annual Meeting 2014
MEDIEN FÜR DIE APOTHEKE
Institutional Sponsors
Förderer der DPhG-Jahrestagung 2014
CONFERENCE COMMITTEES

Scientific Committee
Prof. Dr. Thomas Efferth
Prof. Dr. Christoph Friedrich
Prof. Dr. Peter Gmeiner
Prof. Dr. Ulrike Holzgrabe
Prof. Dr. Ulrich Jaehde
Prof. Dr. Jochen Klein
Prof. Dr. Heyo Kroemer
Prof. Dr. Peter Langguth
Prof. Dr. Stefan Laufer
Prof. Dr. Kristina Friedland
Prof. Dr. Andreas Link
Prof. Dr. Irmgard Merfort
Prof. Dr. Klaus Mohr
Dr. Olaf Queckenberg
Prof. Dr. Peter Ruth
Prof. Dr. Andrea Sinz
Prof. Dr. Angelika Vollmar
Prof. Dr. Hermann Wätzig
Prof. Dr. Werner Weitschies
Prof. Dr. Gerhard Winter

Organisation Committee
Seniorprof. Dr. Theodor Dingermann
Prof. Dr. Jennifer Dressman
PD. Dr. Gunter Eckert
Prof. Dr. Robert Fürst
Dr. Ann-Kathrin Häfner
Dr. Bettina Hofmann
Prof. Dr. Michael Karas
PD. Dr. Thorsten Maier
Prof. Dr. Rolf Marschalek
Jun.-Prof. Dr. Eugen Proschak
Dr. Bernd Sorg
Dr. Michael Stein
Dr. Mario Wurglics

DPhG Annual Meeting 2014 3
ADDRESS OF WELCOME

Dear colleagues,
as President of the German Pharmaceutical Society (DPhG) and congress chair-
man it is a pleasure for me to welcome you at Frankfurt to attend our Annual
place for such a meeting which is part of the GU100 celebrations on the occa-
sion of the 100th birthday of Goethe University. Furthermore, the meeting is
cosponsored by one of our most important partners, the Pharmaceutical Society
of Japan (PSJ).
We can present you an interesting scientific programme which focuses on
recent developments in all pharmaceutical disciplines. The meeting program
covers topics such as antiinflammatory drugs, anticancer drugs and epigenetics,
biotechnology, clinical pharmacy, drug design/medicinal chemistry/analytics,
natural compounds, biopharmaceutics as well as many aspects of pharmaceuti-
cal technology and drug delivery.
I thank the scientific and the organisation committee as well as the chair
Prof. Dr. Dieter Steinhilber
persons of the sessions for creating an exciting programme. I would like to
DPhG President
thank all participants of the meeting for sharing their recent results and for
their contributions. The abstract book provides you with an overview about the
scientific posters and presentations and we hope, it will contribute to a success-
ful meeting and to scientific exchange and discussions.

4
TABLE OF CONTENTS
General Information ................................................................................................................................................................................. 6
Conference Program Overview ............................................................................................................................................................. 7
Plenary lectures ...................................................................................................................................................................................... 15
Scientific Sessions .................................................................................................................................................................................. 23
Antiinflammatory Drugs ................................................................................................................................................................................. 24
Neurodegeneration ........................................................................................................................................................................................... 29
Pharmaceutical Technology and Drug Delivery....................................................................................................................................... 33
Medicinal Chemistry (PSJ) .............................................................................................................................................................................. 38
Biomarker and Modeling ................................................................................................................................................................................ 42
Ligand Binding Assays ..................................................................................................................................................................................... 45
Computational Chemistry and Molecular Design ................................................................................................................................... 49
Natural Compounds ......................................................................................................................................................................................... 54
Analytics ............................................................................................................................................................................................................... 59
Case studies from Pharmaceutical Research and Development ........................................................................................................ 64
GPCR Medicinal Chemistry............................................................................................................................................................................. 69
Industrial Pharmacy ......................................................................................................................................................................................... 73
Biopharmaceutics and Pharmaceutical Technology .............................................................................................................................. 77
Anticancer and Epigenetic Drugs ................................................................................................................................................................. 82
Evidence-based Medication Management ................................................................................................................................................ 86
Optimizing Oral Drug Performance ............................................................................................................................................................. 90
Multitarget Drugs ............................................................................................................................................................................................. 94
Non-canonical GPCR-Signaling ................................................................................................................................................................... 99
Biopharmaceuticals/Biotechnology ........................................................................................................................................................... 103
Short lectures ........................................................................................................................................................................................ 108
Posters ..................................................................................................................................................................................................... 121
Antiinflammatory Drugs (AD01-AD19) .................................................................................................................................................... 122
Anticancer Drugs and Epigenetics (ACE01-ACE33) .............................................................................................................................. 128
Biotechnology (BT01-BT16) ......................................................................................................................................................................... 140
Clinical Pharmacy (CP01-CP15) .................................................................................................................................................................. 147
Drug Design/Medicinal Chemistry/Analytics (MC01-MC62) ............................................................................................................. 153
GPCR (G01-G14) .............................................................................................................................................................................................. 176
Natural Compounds (NC01-NC21) ............................................................................................................................................................ 182
Neuroactive Drugs (ND01-ND13) .............................................................................................................................................................. 189
Biopharmaceutics (BP01-BP09) .................................................................................................................................................................. 194
Pharmaceutical Technology and Drug Delivery (PT01-PT34) ............................................................................................................ 198
Authors Index ........................................................................................................................................................................................ 212

DPhG Annual Meeting 2014 5
GENERAL INFORMATION

INSTRUCTIONS FOR USING CONFERENCE WLAN
If you are a member of an institution (e.g. a university), which is a member of the "eduroam" community, you should use
the wireless network "eduroam". In most cases you can use the wireless network eduroam in the same way you are used
to connect to the wireless network at your home institution. Please use your account and the domain of your institution
(e.g. [email protected]).
If your institution (e.g. a university) is not a member of the "eduroam" community, you have to obtain a guest-account
s-
word. After authenticating successfully, you will have access to the Internet.

ABSTRACT AND POSTER NUMBERS
Each abstract has a unique identifier, a letter-number combination. Letters refer to the conference topic a contribution
was assigned to. For example, a poster presentation in the area of Antiinflammatory Drugs might have the number
AD.01. Short lectures SL
Please note that in the case of poster presentations the abstract number is identical with the poster number.

Please refer to the authors index on page 212 for direct access to specific abstracts.

CONFERENCE OFFICE
The Conference office is located at the Conference building (Otto-Stern-Zentrum (OSZ), S1 / S2).
Opening hours:
Wednesday, September 24th, 2014: 10.00 am 6.00 pm;
Thursday, September 25th, 2014: 8.00 am 6.00 pm;
Friday, September 26th, 2014: 8.00 am 12.00 am.

POSTER SESSIONS
There will be two poster sessions:
Antiinflammatory Drugs, Anticancer Drugs / Biotechnology, Clinical Pharmacy, GPCR, Natural
Topics Epigenetics and Drug Design / Medicinal Chemis- Compounds, Neuroactive Drugs, Biopharmaceu-
try / Analytics tics and Pharmaceutical Technology/Drug Deliv-
ery
Session Wednesday, Sept. 24th, 6 pm until 10 pm Thursday, Sept. 25th, 12 o' clock noon until 1.30
pm
Set-up Wednesday, Sept. 24th, before 6 pm Thursday, Sept. 25th, before 10 am
Dismantling Wednesday, Sept. 24th, after 10 pm Thursday, Sept. 25th, after 6 pm

CONFERENCE DINNER
Separate registration necessary (special fee). Please refer to the Conference Office for registration and details.
The Conference dinner will take place at the Casino on Campus Westend (no public parking available, please use subway
U8 from station Uni Campus Riedberg to station Holzhausenstraße). For detailed maps of Campus Riedberg and Campus
Westend see page 224.

6
CONFERENCE PROGRAM OVERVIEW

Pre-symposia and public talk
Tuesday, 23.9.2014
Bürgersymposium: Advanced Course in Pharmacology Workshop Drittmittelförderung
Frankfurter Pharmaziegeschichte - (DGPT) 'Durchflusszytometrie:  Ort: OSZ (HS 4)
Von Goethe bis Hoechst Anwendungen in pharmakologi-
 Ort: Campus Westend (Foyer PA scher und pharmazeutischer
Gebäude) Forschung
Separate Anmeldung bei der DGPT
erforderlich
 Ort: OSZ (HS 3) 15.00-18.30 Uhr
15.00-15.15: Begrüßung, 15.00-15.10: Einführung, 14.00-16.00: Dos und Don'ts beim
Christoph Friedrich, Marburg Prof. Dr. Detlef Neumann Antragschreiben,
T. Hotopp, DFG
 Ort: OSZ (HS 4)
15.15-16.00: Zur Entwicklung der 15.10-15.55: Einführung in die 16.00-17.00: Horizon 2020,
Pharmazie an der Johann- Durchflusszytometrie, M. Ackermann, Nationale Kontakt-
Wolfgang-Goethe-Universität Dr. Stefan Schnell stelle Lebenswissenschaften
Frankfurt, Fluoreszenz-  Ort: OSZ (HS 4)
Prof. Dr. Axel Helmstädter aktiviertes Zellsortieren mithilfe
der Mikrochip-Technologie,
Dr. Martin Büscher
16.00-16.45: Zur Geschichte des 15.55-16.40: Durchflusszytometrie 15.00-16.30: Beiratssitzung des
Frankfurter Apothekenwesens, für die pharmakologische Charak- VdPPhI
Dr. Caroline Seyfang terisierung von GPCR Liganden,  Ort: OSZ (HS 5)
Prof. Dr. Erich Schneider

16.45-17.15: Kaffeepause 16.40-17.00: Kaffeepause
17.15-18.00: Die Entwicklung der 17.00-17.45: Chipzytometrie für 17.00-19.30: Mitgliederversamm-
Firma Hoechst unter besonderer die - o- lung des VdPPhI
Berücksichtigung ihrer Geschichte marker-Analyse: Technologie und  Ort: OSZ (HS 5)
im Dritten Reich, Anwendung,
Prof. Dr. Stephan H. Lindner Dr. Christian Hennig
18.00-18.45: Eine Tradition der 17.45-18.30: Standardisierung
besonderen Art: Goethe und sein und Automatisierung durch-
Verhältnis zur Pharmazie und zu flusszytometrischer Assays in der
Pharmazeuten, pharmakologischen Forschung,
Prof. Dr. Christoph Friedrich Dr. Peter Engel

anschl. Empfang, Campus Wes-
tend, Foyer PA Gebäude

DPhG Annual Meeting 2014 7
CONFERENCE PROGRAM OVERVIEW

Wednesday, 24.9.2014
Fachgruppen-Meetings
OSZ H2 OSZ H3 OSZ H4 OSZ H5 OSZ H6
9.00-10.30 Pharmazie 2020,
D. Steinhilber,
S. Laufer
10.30-12.00 Fachgruppe Fachgruppe Fachgruppe Klin. Fachgruppe Fachgruppe
Pharm./Med. Pharmakologie, Pharmazie, Pharm. Biologie, Pharm. Techno-
Chemie, J. Klein K. Friedland A. Vollmar logie,
P. Gmeiner P. Langguth

Wednesday, 24.9.2014
Main Symposium (Congress language English)

13.00-13.30 Opening of the Annual DPhG Meeting 2014,
Trends and Perspectives in Pharmaceutical Sciences
OSZ H1+H2
13.30-14.15 PL 1, Peter Ruth, New disease relevant functions of Ca2+-activated potassium channels
OSZ H1+H2
14.15-15.00 PL 2, Shinji Yamashita, Streamlining the development of oral drug product: Role of researchers in
academia
OSZ H1+H2
15.00-15.30 Coffee break
OSZ
Short talks, parallel sessions I
15.30-17.00 OSZ H3 OSZ H4 OSZ H5
Antiinflammatory Drugs Neurodegeneration Pharmaceutical Technology
Chair: Chair: and Drug Delivery
S. Laufer, D. Steinhilber C. Culmsee, J. Klein Chair:
L. Meinel, W. Weitschies

15.30 Jan Schwab, 15.30 Carsten Culmsee, 15.30 Markus Thommes,
Resolvins, protectins and New insights into Bid- Formulation strategies for
maresins as candidates to mediated mitochondrial poorly water soluble drugs
propagate resolution of in- demise in neuronal cell death
flammation in lesions of the
central nervous system (CNS)
15.50 Andreas Köberle, 15.55 Jochen Klein, 15.50 Stephan Reichl,
Functional lipidomics reveals Experimental stroke research: Valid cell culture models of
phosphatidylcholine-bound problems and opportunities the human cornea for drug
arachidonic acid as regulator transport investigations -
of protein kinase B where are we?

16.10 Thorsten Maier, 16.20 Carina Hohmann, 16.10 Tessa Charlotte Lüh-
Nitro lipids as novel regulators Emerging options for pharma- mann,
of leukotriene biosynthesis ceutical care in stroke patients Protein engineering of fibro-
blast growth factor 2 (FGF-2)
for bioresponsive protein
delivery

8